199 related articles for article (PubMed ID: 35514075)
21. Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study.
Boeri M; Milione M; Proto C; Signorelli D; Lo Russo G; Galeone C; Verri C; Mensah M; Centonze G; Martinetti A; Sottotetti E; Pastorino U; Garassino MC; Sozzi G
Clin Cancer Res; 2019 Apr; 25(7):2166-2173. PubMed ID: 30617131
[TBL] [Abstract][Full Text] [Related]
22. Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer.
Liu C; Yang L; Xu H; Zheng S; Wang Z; Wang S; Yang Y; Zhang S; Feng X; Sun N; Wang Y; He J
BMC Med; 2022 May; 20(1):187. PubMed ID: 35550592
[TBL] [Abstract][Full Text] [Related]
23. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K
Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552
[TBL] [Abstract][Full Text] [Related]
24. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
[TBL] [Abstract][Full Text] [Related]
25. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
26. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes.
Doroshow DB; Sanmamed MF; Hastings K; Politi K; Rimm DL; Chen L; Melero I; Schalper KA; Herbst RS
Clin Cancer Res; 2019 Aug; 25(15):4592-4602. PubMed ID: 30824587
[TBL] [Abstract][Full Text] [Related]
28. Baseline extracellular vesicle TGF-β is a predictive biomarker for response to immune checkpoint inhibitors and survival in non-small cell lung cancer.
de Miguel-Perez D; Russo A; Gunasekaran M; Buemi F; Hester L; Fan X; Carter-Cooper BA; Lapidus RG; Peleg A; Arroyo-Hernández M; Cardona AF; Naing A; Hirsch FR; Mack PC; Kaushal S; Serrano MJ; Adamo V; Arrieta O; Rolfo C
Cancer; 2023 Feb; 129(4):521-530. PubMed ID: 36484171
[TBL] [Abstract][Full Text] [Related]
29. Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition.
Tarhoni I; Wakefield CJ; Kollipara R; Fidler MJ; Batus M; Bonomi P; Borgia JA
J Immunol Methods; 2021 Mar; 490():112956. PubMed ID: 33434603
[TBL] [Abstract][Full Text] [Related]
30. Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer.
Zhao S; Gao G; Li W; Li X; Zhao C; Jiang T; Jia Y; He Y; Li A; Su C; Ren S; Chen X; Zhou C
Lung Cancer; 2019 Apr; 130():10-17. PubMed ID: 30885328
[TBL] [Abstract][Full Text] [Related]
31. Real-world evidenceand clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors.
Song P; Zhang J; Shang C; Zhang L
Sci Rep; 2019 Mar; 9(1):4278. PubMed ID: 30862891
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non-small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study.
Luciani A; Marra A; Toschi L; Cortinovis D; Fava S; Filipazzi V; Tuzi A; Cerea G; Rossi S; Perfetti V; Rossi A; Giannetta L; Sala L; Finocchiaro G; Pizzutilo EG; Carelli S; Agustoni F; Cergnul M; Zonato S; Siena S; Bidoli P; Ferrari D
Clin Lung Cancer; 2020 Nov; 21(6):e567-e571. PubMed ID: 32591311
[TBL] [Abstract][Full Text] [Related]
33. [A Real-world Study on the Expression Characteristics of PD-L1 in Patients
with Advanced EGFR Positive NSCLC and Its Relationship with the
Therapeutic Efficacy of EGFR-TKIs].
Chen R; Gao X; Xu F; Zhang S; Ma L; Hu B
Zhongguo Fei Ai Za Zhi; 2023 Mar; 26(3):217-227. PubMed ID: 37035884
[TBL] [Abstract][Full Text] [Related]
34. Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50.
Gainor JF; Rizvi H; Jimenez Aguilar E; Skoulidis F; Yeap BY; Naidoo J; Khosrowjerdi S; Mooradian M; Lydon C; Illei P; Zhang J; Peterson R; Ricciuti B; Nishino M; Zhang J; Roth JA; Grishman J; Anderson D; Little BP; Carter BW; Arbour K; Sauter JL; Mino-Kenudson M; Heymach JV; Digumarthy S; Shaw AT; Awad MM; Hellmann MD
Ann Oncol; 2020 Mar; 31(3):404-411. PubMed ID: 32067682
[TBL] [Abstract][Full Text] [Related]
35. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
[TBL] [Abstract][Full Text] [Related]
36. Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - A systematic review and network meta-analysis of 3024 participants.
Tan PS; Aguiar P; Haaland B; Lopes G
Lung Cancer; 2018 Jan; 115():84-88. PubMed ID: 29290267
[TBL] [Abstract][Full Text] [Related]
37. FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC.
Spigel DR; Chaft JE; Gettinger S; Chao BH; Dirix L; Schmid P; Chow LQM; Hicks RJ; Leon L; Fredrickson J; Kowanetz M; Sandler A; Funke R; Rizvi NA
J Thorac Oncol; 2018 Nov; 13(11):1733-1742. PubMed ID: 29775807
[TBL] [Abstract][Full Text] [Related]
38. Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients.
Li C; Li C; Zhi C; Liang W; Wang X; Chen X; Lv T; Shen Q; Song Y; Lin D; Liu H
J Transl Med; 2019 Oct; 17(1):355. PubMed ID: 31665020
[TBL] [Abstract][Full Text] [Related]
39. [The efficacy and prognostic factors of immunotherapy in advanced non-small cell lung cancer patients with different driver gene mutations].
Ma SX; Ma N; Han J; He Z; Wang L; Wang Q
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):922-929. PubMed ID: 35385963
[No Abstract] [Full Text] [Related]
40. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
